RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Investor Presentation (May 2015)
5 slides from RespireRx Pharmaceuticals's investor presentation, May 18, 2015
Slide 1: Cortex Pharmaceuticals, Inc.
HICTEX PHAFAMCEUTICAS, NC Cortex Pharmaceuticals, Inc. May 15, 2015
Slide 2: Background
Background 2013 + Insolvent & near bankruptcy No ongoing operations Lost dronabinol license Deficient in SEC reporting Approx. $3M market cap Today + Non-bankruptcy reorganization + New capital raised + Re-gained dronabinol license + Current in SEC reporting + Approx. $25M market cap + Newly organiz
Slide 3: Dronabinol for Treatment of OSA: A Phase 2 Compound
abinol for Treatment of OSA: A Phase 2 Compound Mechanism of Action = Dronabinol is (4-9)THC, a cannabinoid agonist Commercial Status = FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy = Schedule III drug available by pres
Slide 4: Dronabinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea
abinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea ° Phase 2B study in progress at University of Illinois ° 120 subjects (40/group, 6 wks dosing) ° Doses: Placebo, 2.5 mg, 10 mg qd » Study costs funded by NIH Grant for $5 MM ° Top line data by May 2016 | —_—
Slide 5: Key Objectives for the Next Months
Key Objectives for the Next 12 Months Compound Indication Status Estimated Estimated Start Date Goan Dronabinol Obstructive Sleep Apnea Phase IIB started May 2016 Opiate-induced RD Phase A 2Q2015 3Q2015 X1739 = Propofol-induced RD Phase A 3Q2015 4Q2015 CIE | pci Phase ILA 4Q2015 2Q2016 X717 cx1942 I
Cortex Pharmaceuticals — Investor Presentation (May 2015) on 6ix